vs
Apellis Pharmaceuticals, Inc.（APLS）与TENNANT CO（TNC）财务数据对比。点击上方公司名可切换其他公司
TENNANT CO的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$291.6M vs $199.9M），TENNANT CO净利率更高（-1.5% vs -29.5%，领先28.0%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -11.3%），TENNANT CO自由现金流更多（$9.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -3.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
天纳公司（Tennant Company）是一家清洁产品供应商，拥有约4000名员工，其股票在纽约证券交易所挂牌上市，专注为各类商业及工业场景提供专业清洁相关产品与解决方案。
APLS vs TNC — 直观对比
营收规模更大
TNC
是对方的1.5倍
$199.9M
营收增速更快
APLS
高出5.4%
-11.3%
净利率更高
TNC
高出28.0%
-29.5%
自由现金流更多
TNC
多$24.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
-3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $291.6M |
| 净利润 | $-59.0M | $-4.4M |
| 毛利率 | — | 34.6% |
| 营业利润率 | -25.6% | -1.4% |
| 净利率 | -29.5% | -1.5% |
| 营收同比 | -5.9% | -11.3% |
| 净利润同比 | -62.2% | -166.7% |
| 每股收益（稀释后） | $-0.40 | $-0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTNC
| Q4 25 | $199.9M | $291.6M | ||
| Q3 25 | $458.6M | $303.3M | ||
| Q2 25 | $178.5M | $318.6M | ||
| Q1 25 | $166.8M | $290.0M | ||
| Q4 24 | $212.5M | $328.9M | ||
| Q3 24 | $196.8M | $315.8M | ||
| Q2 24 | $199.7M | $331.0M | ||
| Q1 24 | $172.3M | $311.0M |
净利润APLSTNC
| Q4 25 | $-59.0M | $-4.4M | ||
| Q3 25 | $215.7M | $14.9M | ||
| Q2 25 | $-42.2M | $20.2M | ||
| Q1 25 | $-92.2M | $13.1M | ||
| Q4 24 | $-36.4M | $6.6M | ||
| Q3 24 | $-57.4M | $20.8M | ||
| Q2 24 | $-37.7M | $27.9M | ||
| Q1 24 | $-66.4M | $28.4M |
毛利率APLSTNC
| Q4 25 | — | 34.6% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 42.1% | ||
| Q1 25 | — | 41.4% | ||
| Q4 24 | — | 41.3% | ||
| Q3 24 | — | 42.4% | ||
| Q2 24 | — | 43.1% | ||
| Q1 24 | — | 44.2% |
营业利润率APLSTNC
| Q4 25 | -25.6% | -1.4% | ||
| Q3 25 | 48.7% | 7.4% | ||
| Q2 25 | -18.6% | 9.6% | ||
| Q1 25 | -50.0% | 6.8% | ||
| Q4 24 | -12.3% | 2.3% | ||
| Q3 24 | -24.0% | 9.7% | ||
| Q2 24 | -14.7% | 11.7% | ||
| Q1 24 | -36.0% | 12.1% |
净利率APLSTNC
| Q4 25 | -29.5% | -1.5% | ||
| Q3 25 | 47.0% | 4.9% | ||
| Q2 25 | -23.6% | 6.3% | ||
| Q1 25 | -55.3% | 4.5% | ||
| Q4 24 | -17.1% | 2.0% | ||
| Q3 24 | -29.2% | 6.6% | ||
| Q2 24 | -18.9% | 8.4% | ||
| Q1 24 | -38.5% | 9.1% |
每股收益（稀释后）APLSTNC
| Q4 25 | $-0.40 | $-0.21 | ||
| Q3 25 | $1.67 | $0.80 | ||
| Q2 25 | $-0.33 | $1.08 | ||
| Q1 25 | $-0.74 | $0.69 | ||
| Q4 24 | $-0.30 | $0.35 | ||
| Q3 24 | $-0.46 | $1.09 | ||
| Q2 24 | $-0.30 | $1.45 | ||
| Q1 24 | $-0.54 | $1.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $273.2M |
| 股东权益账面价值 | $370.1M | $601.6M |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资APLSTNC
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSTNC
| Q4 25 | — | $273.2M | ||
| Q3 25 | — | $238.3M | ||
| Q2 25 | — | $213.4M | ||
| Q1 25 | — | $213.3M | ||
| Q4 24 | — | $198.2M | ||
| Q3 24 | — | $208.6M | ||
| Q2 24 | — | $205.6M | ||
| Q1 24 | $93.1M | $207.4M |
股东权益APLSTNC
| Q4 25 | $370.1M | $601.6M | ||
| Q3 25 | $401.2M | $640.9M | ||
| Q2 25 | $156.3M | $651.9M | ||
| Q1 25 | $164.2M | $624.4M | ||
| Q4 24 | $228.5M | $620.8M | ||
| Q3 24 | $237.1M | $647.2M | ||
| Q2 24 | $264.3M | $624.6M | ||
| Q1 24 | $266.7M | $614.6M |
总资产APLSTNC
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B | ||
| Q1 24 | $831.9M | $1.2B |
负债/权益比APLSTNC
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | — | 0.33× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | 0.35× | 0.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $14.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $9.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 3.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $43.3M |
8季度趋势，按日历期对齐
经营现金流APLSTNC
| Q4 25 | $-14.2M | $14.2M | ||
| Q3 25 | $108.5M | $28.7M | ||
| Q2 25 | $4.4M | $22.5M | ||
| Q1 25 | $-53.4M | $-400.0K | ||
| Q4 24 | $19.4M | $37.5M | ||
| Q3 24 | $34.1M | $30.7M | ||
| Q2 24 | $-8.3M | $18.6M | ||
| Q1 24 | $-133.0M | $2.9M |
自由现金流APLSTNC
| Q4 25 | $-14.3M | $9.7M | ||
| Q3 25 | $108.3M | $22.3M | ||
| Q2 25 | $4.4M | $18.7M | ||
| Q1 25 | $-53.4M | $-7.4M | ||
| Q4 24 | $19.3M | $28.1M | ||
| Q3 24 | — | $26.4M | ||
| Q2 24 | $-8.4M | $14.4M | ||
| Q1 24 | $-133.3M | $-100.0K |
自由现金流率APLSTNC
| Q4 25 | -7.1% | 3.3% | ||
| Q3 25 | 23.6% | 7.4% | ||
| Q2 25 | 2.5% | 5.9% | ||
| Q1 25 | -32.0% | -2.6% | ||
| Q4 24 | 9.1% | 8.5% | ||
| Q3 24 | — | 8.4% | ||
| Q2 24 | -4.2% | 4.4% | ||
| Q1 24 | -77.3% | -0.0% |
资本支出强度APLSTNC
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 2.9% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.2% | 1.0% |
现金转化率APLSTNC
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.93× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | -0.03× | ||
| Q4 24 | — | 5.68× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 0.67× | ||
| Q1 24 | — | 0.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TNC
| Equipment Sales | $165.5M | 57% |
| Parts And Consumables | $69.1M | 24% |
| Service And Other | $57.0M | 20% |
